Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.



<ul>
<li>HC Wainwright &amp; Co. analyst Robert Burns downgraded ADC Therapeutics SA (NYSE:ADCT) from Buy to Neutral. ADC Therapeutics shares closed at $1.0250 on Friday. See how other analysts view this stock.</li>



<li>Wells Fargo analyst Elyse Greenspan downgraded W. R. Berkley Corporation (NYSE:WRB) from Equal-Weight to Underweight and lowered the price target from $64 to $58. WR Berkley shares closed at $68.57 on Friday. See how other analysts view this stock.</li>
</ul>



Considering buying ADCT stock? Here’s what analysts think:



<figure class="wp-block-image size-large is-resized"><img width="1024" height="449" src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/06/08095939/image-165-1024x449.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/06/08095939/image-165-1024x449.png"/></figure>



Photo via Shutterstock

ADCT

Wall Street analysts downgraded two stocks: HC Wainwright & Co. lowered ADC Therapeutics (ADCT) from Buy to Neutral, while Wells Fargo cut W. R. Berkley (WRB) from Equal-Weight to Underweight and reduced its price target to $58.

benzinga_article

ADC Therapeutics SA

WR Berkley

This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday